NDAORALTABLETPriority Review
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KRINTAFEL (tafenoquine succinate) is an oral small-molecule antimalarial approved by the FDA in July 2018 for the treatment and prevention of malaria. It is indicated for prevention of relapse in patients with Plasmodium vivax malaria who have completed treatment for acute uncomplicated P. vivax malaria with an artemisinin-based combination therapy (ACT). Tafenoquine works as an 8-aminoquinoline that targets hypnozoites, the dormant liver stage parasites responsible for relapse.
$0.003BPart D
PeakProduct is in peak lifecycle stage with modest Part D penetration (26 claims in 2023), indicating a specialized niche market with stable but limited commercial potential for team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KRINTAFEL offers career opportunities primarily in specialized infectious disease and travel medicine segments, with emphasis on market access and niche field sales. The product's peak lifecycle stage and low commercial intensity suggest a focused, lean team structure rather than high-growth headcount expansion.
Brand ManagerField Sales Representative
Worked on KRINTAFEL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.